Short answer
Liquidia Corp (LQDA) filed an 8-K current report with the SEC on September 3, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Item 8.01 references Liquidia’s September 3, 2026 press release as Exhibit 99.1.
Liquidia Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Item 8.01 references Liquidia’s September 3, 2026 press release as Exhibit 99.1
- Investor-relevant event details are contained in the referenced press release
- Filing signed by Michael Kaseta, Chief Financial Officer and Chief Operating Officer
Item EX-99.1 · Exhibit EX-99.1
- FDA Fast Track designation for YUTREPIA in SSc-RP, potentially enabling closer FDA interaction and rolling NDA review
- Addressable U.S. population estimated at approximately 30,000 moderate-to-severe SSc-RP patients
- RE-WARM Phase 2a study planned for October 2026, enrolling approximately 75 adults across up to 30 sites
- Primary completion targeted for February 2027, creating a near-term clinical catalyst
- SSc-RP indication remains unapproved and unvalidated; Fast Track does not ensure efficacy or eventual FDA approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Liquidia Corp 8-K filings
Get the next LQDA 8-K as it lands
Follow LQDA for push alerts, or ask the research agent what this filing means.